- Home
- RNAC
as of 12-12-2025 3:38pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 204.6M | IPO Year: | 2016 |
| Target Price: | $38.40 | AVG Volume (30 days): | 192.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.98 - $23.93 | Next Earning Date: | 11-06-2025 |
| Revenue: | $1,091,000 | Revenue Growth: | -97.72% |
| Revenue Growth (this year): | -94.81% | Revenue Growth (next year): | -66.06% |
AI-Powered RNAC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
Director
Avg Cost/Share
$6.86
Shares
30,000
Total Value
$205,797.00
Owned After
54,366
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BARABE TIMOTHY C | RNAC | Director | Dec 4, 2025 | Buy | $6.86 | 30,000 | $205,797.00 | 54,366 |
Compare RNAC vs Leading Stocks
See how RNAC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.